{"id":"NCT01497262","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis","officialTitle":"A 4-month, Open-label, Multi-center Study to Explore the Safety and Tolerability of Fingolimod 0.5 mg in Patients With Relapsing-remitting Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2011-12-22","resultsPosted":"2015-03-19","lastUpdate":"2015-03-19"},"enrollment":162,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Fingolimod","otherNames":[]}],"arms":[{"label":"Fingolimod","type":"EXPERIMENTAL"}],"summary":"This 4 month, open-label study will evaluate the safety and tolerability of fingolimod 0.5 mg in patients with relapsing-remitting multiple sclerosis (RRMS) and generate additional data in Multiple Sclerosis (MS) patient population that closely resembles the clinical population seen in routine medical care.","primaryOutcome":{"measure":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability","timeFrame":"28 weeks","effectByArm":[{"arm":"Fingolimod 0.5 mg","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":11},"locations":{"siteCount":29,"countries":["Argentina","Brazil","Colombia","Jordan","Malaysia","Mexico","Panama","Peru"]},"refs":{"pmids":["26170105"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":162},"commonTop":["Headache","Lymphopenia","Fatigue","Diarrhoea","Upper respiratory tract infection"]}}